{"schema_version":"secwatch.filing_event.v1","accession":"0001837607-24-000077","form_type":"8-K","ticker":"AEON","cik":"0001837607","company_name":"AEON Biopharma, Inc.","filed_at":"2024-07-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.810741+00:00","generated_at":"2026-05-31T22:39:02.604284+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AEON Biopharma shifts ABP-450 to biosimilar pathway targeting BOTOX; plans pivotal study in cervical dystonia","bullets":["ABP-450 will pursue 351(k) biosimilar pathway using AbbVie's BOTOX as reference product.","Company plans a single pivotal Phase 3 comparative study in cervical dystonia.","Successful Phase 3 could support biosimilar determination for up to 8 therapeutic indications.","Biosimilar Initial Advisory Meeting with FDA scheduled for Q3 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001837607-24-000077","json":"https://secwatch.observer/filing/0001837607-24-000077.json","markdown":"https://secwatch.observer/filing/0001837607-24-000077.md","text":"https://secwatch.observer/filing/0001837607-24-000077.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1837607/000183760724000077/0001837607-24-000077-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1837607/000183760724000077/aeon-20240709x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T22:39:02.604284+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}